A Minipress antilipidaemiás hatásáról.

Translated title of the contribution: The anti-lipidemic effect of Minipress

G. Pados, J. Iványi, I. Földes, M. Dudás, C. Farsang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prazosin (Minipress) monotherapy was given to 152 patients with essential hypertension for one year in a multi-center study involving 13 hospitals and university clinics. In three centers serum levels of total cholesterol, HDL-cholesterol and triglycerides were also determined in 32 patients with hypertension and hyper/dys-lipoproteinemia. As a consequence of Minipress monotherapy significant decreases were found in serum level of cholesterol (after three months and also after one year), triglycerides (after one year), while the serum concentration of HDL-cholesterol increased. Atherogenic index (a ratio of total cholesterol over HDL-cholesterol) was significantly decreased by Minipress. As new data showing a causative correlation between hypertension and hyperlipoproteinemia were published in the literature authors, on the basis of their results, suggest to determine lipid profile in every patient with hypertension. They regard Minipress as the first line drug in young patients with "familial dyslipidemic hypertension". When choosing an antihypertensive drug metabolic side effects should be taken into consideration.

Original languageHungarian
Pages (from-to)1139-1141
Number of pages3
JournalOrvosi Hetilap
Volume131
Issue number21
Publication statusPublished - May 27 1990

Fingerprint

Prazosin
HDL Cholesterol
Hypertension
Cholesterol
Triglycerides
Serum
Hyperlipoproteinemias
Drug-Related Side Effects and Adverse Reactions
Antihypertensive Agents
Lipids
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pados, G., Iványi, J., Földes, I., Dudás, M., & Farsang, C. (1990). A Minipress antilipidaemiás hatásáról. Orvosi Hetilap, 131(21), 1139-1141.

A Minipress antilipidaemiás hatásáról. / Pados, G.; Iványi, J.; Földes, I.; Dudás, M.; Farsang, C.

In: Orvosi Hetilap, Vol. 131, No. 21, 27.05.1990, p. 1139-1141.

Research output: Contribution to journalArticle

Pados, G, Iványi, J, Földes, I, Dudás, M & Farsang, C 1990, 'A Minipress antilipidaemiás hatásáról.', Orvosi Hetilap, vol. 131, no. 21, pp. 1139-1141.
Pados G, Iványi J, Földes I, Dudás M, Farsang C. A Minipress antilipidaemiás hatásáról. Orvosi Hetilap. 1990 May 27;131(21):1139-1141.
Pados, G. ; Iványi, J. ; Földes, I. ; Dudás, M. ; Farsang, C. / A Minipress antilipidaemiás hatásáról. In: Orvosi Hetilap. 1990 ; Vol. 131, No. 21. pp. 1139-1141.
@article{1b60020b4e86453a934f4cd8135d8d8e,
title = "A Minipress antilipidaemi{\'a}s hat{\'a}s{\'a}r{\'o}l.",
abstract = "Prazosin (Minipress) monotherapy was given to 152 patients with essential hypertension for one year in a multi-center study involving 13 hospitals and university clinics. In three centers serum levels of total cholesterol, HDL-cholesterol and triglycerides were also determined in 32 patients with hypertension and hyper/dys-lipoproteinemia. As a consequence of Minipress monotherapy significant decreases were found in serum level of cholesterol (after three months and also after one year), triglycerides (after one year), while the serum concentration of HDL-cholesterol increased. Atherogenic index (a ratio of total cholesterol over HDL-cholesterol) was significantly decreased by Minipress. As new data showing a causative correlation between hypertension and hyperlipoproteinemia were published in the literature authors, on the basis of their results, suggest to determine lipid profile in every patient with hypertension. They regard Minipress as the first line drug in young patients with {"}familial dyslipidemic hypertension{"}. When choosing an antihypertensive drug metabolic side effects should be taken into consideration.",
author = "G. Pados and J. Iv{\'a}nyi and I. F{\"o}ldes and M. Dud{\'a}s and C. Farsang",
year = "1990",
month = "5",
day = "27",
language = "Hungarian",
volume = "131",
pages = "1139--1141",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "21",

}

TY - JOUR

T1 - A Minipress antilipidaemiás hatásáról.

AU - Pados, G.

AU - Iványi, J.

AU - Földes, I.

AU - Dudás, M.

AU - Farsang, C.

PY - 1990/5/27

Y1 - 1990/5/27

N2 - Prazosin (Minipress) monotherapy was given to 152 patients with essential hypertension for one year in a multi-center study involving 13 hospitals and university clinics. In three centers serum levels of total cholesterol, HDL-cholesterol and triglycerides were also determined in 32 patients with hypertension and hyper/dys-lipoproteinemia. As a consequence of Minipress monotherapy significant decreases were found in serum level of cholesterol (after three months and also after one year), triglycerides (after one year), while the serum concentration of HDL-cholesterol increased. Atherogenic index (a ratio of total cholesterol over HDL-cholesterol) was significantly decreased by Minipress. As new data showing a causative correlation between hypertension and hyperlipoproteinemia were published in the literature authors, on the basis of their results, suggest to determine lipid profile in every patient with hypertension. They regard Minipress as the first line drug in young patients with "familial dyslipidemic hypertension". When choosing an antihypertensive drug metabolic side effects should be taken into consideration.

AB - Prazosin (Minipress) monotherapy was given to 152 patients with essential hypertension for one year in a multi-center study involving 13 hospitals and university clinics. In three centers serum levels of total cholesterol, HDL-cholesterol and triglycerides were also determined in 32 patients with hypertension and hyper/dys-lipoproteinemia. As a consequence of Minipress monotherapy significant decreases were found in serum level of cholesterol (after three months and also after one year), triglycerides (after one year), while the serum concentration of HDL-cholesterol increased. Atherogenic index (a ratio of total cholesterol over HDL-cholesterol) was significantly decreased by Minipress. As new data showing a causative correlation between hypertension and hyperlipoproteinemia were published in the literature authors, on the basis of their results, suggest to determine lipid profile in every patient with hypertension. They regard Minipress as the first line drug in young patients with "familial dyslipidemic hypertension". When choosing an antihypertensive drug metabolic side effects should be taken into consideration.

UR - http://www.scopus.com/inward/record.url?scp=0025715148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025715148&partnerID=8YFLogxK

M3 - Article

C2 - 2362761

AN - SCOPUS:0025715148

VL - 131

SP - 1139

EP - 1141

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 21

ER -